Emerald Bioscience Provides Update on Recent Progress and Expected 2020 Milestones
13. Januar 2020 08:30 ET
|
Emerald Bioscience, Inc.
Company prepares to enter the clinic in 2020 to test NB1111 (THCVHS) in glaucoma Preclinical formulation testing proprietary analog of CBD examining the utility of CBDVHS in the eye, brain, and...
Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma
15. Oktober 2019 08:30 ET
|
Emerald Bioscience, Inc.
Study Points to Unique Link Between the Endocannabinoid System and the Inflammatory Cascade in the Eye LONG BEACH, CA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc....